Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF™ Therapy at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)

USA - English

• USA - español

ST. HELIER, Jersey, Nov. 18, 2013 /PRNewswire/ -- Novocure announced today that 15 preclinical and clinical abstracts describing the latest aspects of NovoTTF™ Therapy will be presented at the 4^th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO), which is being held in conjunction with the 18^th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in San Francisco, California from November 21-24, 2013.

"We are pleased to announce that multiple abstracts evaluating NovoTTF Therapy and its role in the treatment of brain cancer will be presented at this very prestigious medical congress. The majority of these abstracts are by renowned neuro-oncology experts from around the globe. Collectively, the growing body of evidence further supports NovoTTF Therapy in the treatment of recurrent glioblastoma and further elucidates the mechanisms of action of NovoTTF Therapy as an anti-cancer treatment," said Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.

In addition to the data presentations, Novocure has provided an unrestricted grant for a continuing medical educational program on central nervous system tumors that will be held on Thursday, November 21 at 7:30pm PT. More information about this program including registration information can be found by accessing www.researchtopractice.com.

Novocure is also sponsoring a lunch symposium on Saturday, November 23 at 12:00pm that will focus on practical considerations for NovoTTF Therapy in the treatment of recurrent Glioblastoma.

Title: NovoTTF Therapy:  A New Frontier in Recurrent Glioblastoma

Faculty:  Steven Toms, MD (Geisinger Medical System), Ashley Sumrall, MD (Levine Cancer Center and Eilon Kirson, MD, PhD (Novocure)

Location: San Francisco Marriott Marquis Hotel, Yerba Buena 12:00 – 1:00 PM

Detailed information about the data presentations are listed below:

Poster sessions on Friday, November 22, 7-9pm:

Phase III trial of Tumor Treating Fields (TTFields) together with temozolomide (TMZ) compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM). Presenter: Ori Farber, Novocure, Israel.  Poster: MR-008.

Use of NovoTTF-100A^TM in heavily pre-treated patients with relapsed high grade glioma: a retrospective chart review. Presenter: Ashley Sumrall, Carolinas Healthcare System, Medical University of South Carolina USA.  Poster: MR-032,

A phase II randomized study of TTFields therapy versus supportive care in non-small cell lung cancer (NSCLC) patients with 1-3 brain metastases (BM) following stereotactic radio-surgery (SRS).  Presenter: Uri Weinberg, Novocure, Switzerland.  Poster: MR-036.

Radiographic response of an incidental meningioma in a patient with glioblastoma on NovoTTF therapy.  Presenter: Lauren Schaff, Columbia University, USA.  Poster: NO-006.

Tumor Treating Fields (TTFields) in recurrent GBM. An updated subgroup analysis of the Phase III data.  Presenter: Andrew Kanner, Tel Aviv Sourasky Medical Center, Israel.  Poster: NO-065.

The effect of field strength on GBM response in patients treated with Novocure-TTF. Presenter: Scott Turner, Geisinger Medical Center, USA.   Poster: NO-134.

Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure.   Presenter: Eric T. Wong, Beth Israel Deaconess Medical Center, USA.  Poster: NO-146.

Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas.  Presenter: Grace Elzinga, Beth Israel Deaconess Medical Center, USA.  Poster: NO-147.

Poster sessions on Saturday, November 23, 5-7pm:

Alternating electric fields (TTFields) inhibit DNA damage repair response in cancer cell lines.  Presenter: Moshe Giladi, Novocure Ltd., Israel.   Poster: ET-028.

Overcoming cell size escape from tumor treating fields using a varying frequency treatment paradigm in-vitro.  Presenter: Moshe Giladi, Novocure Ltd., Israel.  Poster: ET-029.

Analysis of combination of Tumor Treating Fields (TTFields) with radiotherapy in non-small cell lung cancer.   Presenter: Katarzyna Zielinska-Chomej, Karolinska Institutet, Sweden.  Poster: ET-033.

Disruption of cell division within anaphase by tumor treating electric fields (TTFields) leads to immunogenic cell death.   Presenter: Sze Xian Lee, Beth Israel Deaconess Medical Center, USA.  Poster: IR-022.

Meta-analysis of cancer cell line genomes based on their response to alternating electric fields (TTFields).   Presenter: Moshe Giladi, Novocure Ltd. Israel.  Poster: MP-005.

Electric fields for the treatment of glioblastomas: a modeling study.   Presenter: Cornelia Wenger, University of Lisbon, Portugal.  Poster: TM-028.

Dermatologic event characteristics and management with the NovoTTF-100A System, a novel antimitotic device for the treatment of recurrent glioblastoma.   Presenter: Mario Lacouture, Memorial Sloan-Kettering Cancer Center, USA.  Poster: SM-014.

About The NovoTTF-100A System
The NovoTTF-100A System is a wearable, non-invasive anti-mitotic device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow or reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.The portable delivery system creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. The NovoTTF-100A System, a NovoTTF Therapy delivery system, has received marketing approval in the United States (U.S.) and is a CE Marked device cleared for sale in the European Union, Switzerland, Australia and Israel.

Approved Indication
The U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following confirmed disease recurrence. The device is intended to be used as monotherapy as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.

Full prescribing information is available at NovoTTFTherapy.com or by calling toll free 1-855-281-9301.NovoTTF Therapy is experimental for the treatment of newly diagnosed glioblastoma. Limited by law to investigational use only.  NovoTTF Therapy is not approved for the treatment of brain metastases, meningiomas or NSCLC. The safety and efficacy of NovoTTF Therapy for these indications has not been established.

About Novocure™
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure Inc., Novocure's U .S. subsidiary, has operations in New York, NY and Portsmouth, NH. Novocure's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Contact:
Peter Melnyk, Novocure
[email protected]
(212) 767-7534

SOURCE Novocure

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED